Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-12
2007-06-12
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388900, C530S391300, C530S304000, C436S548000
Reexamination Certificate
active
10305268
ABSTRACT:
The present invention relates to an antibody or antibody fragment that binds to 1,4,7,10-tetrazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA),which is bound to an alkyl-amino group through one of its pendant carb.oxyl groups.
REFERENCES:
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5663301 (1997-09-01), Johnson
patent: 5811267 (1998-09-01), Ring
patent: 5827690 (1998-10-01), Meade et al.
patent: 5973116 (1999-10-01), Epenetos et al.
patent: 6458933 (2002-10-01), Hansen
patent: 2002/0076406 (2002-06-01), Leung
patent: 0 369 567 (1990-05-01), None
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Attwood et al, The Babel of Bioinformatics, 2000, Science vol. 290 No. 5491: 471-473.
Kuby et al, Immunology, Second edition, pp. 86-96, 1994.
Castel et al, J Histochem Cytochem 26(7): 581-592, Jul. 1978.
Denardo et al., “Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics,”Clinical Cancer Research, Oct. 1999, pp. 3213s-3218s, vol. 5, No. 10 Suppl.
Perico et al., “The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule,”Journal of Nuclear Medicine, Nov. 2001, pp. 1697-1703, vol. 42, No. 11, Society of Nuclear Medicine, U.S.A.
Govindan et al., “Advances in the use of monoclonal antibodies in cancer radiotherapy,”Pharmaceutical Science&Technology Today, Mar. 2000, pp. 90-98, vol. 3, No. 3.
Govindan et al., “Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: Radiolabeling and animal biodistribution studies,”Bioconjugate Chemistry, Nov. 1998, pp. 773-782, vol. 9, No. 6.
Barbas III et al., “Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen-Specific Fabs,”Methods: A Comparison to Methods in Enzymology, Apr. 1991, pp. 119-124, vol. 2, No. 2.
Barbet et al., “Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium Bispecific Antibody,”The Journal of Nuclear Medicine, Jul. 1998, pp. 1172-1178, vol. 39, No. 7.
Bardiès et al., “Bispecific Antibody and Iodine-131-Labeled Bivalent Hapten Dosimetry in Patients with Medullary Thyroid or Small-Cell Lung Cancer,”The Journal of Nuclear Medicine, Nov. 1996, pp. 1853-1859, vol. 37, No. 11.
Baxter et al., “Pharmacokinetic Analysis of the Perivascular Distribution of Bifunctional Antibodies and Haptens: Comparison with Experimental Data,”Cancer Research, Oct. 15, 1992, pp. 5838-5844, vol. 52, No. 20.
Bei et al., “Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein,”Journal of Imunological Methods, 1995, pp. 245-255, vol. 186.
Boden et al., “Preliminary Study of the Metal Binding Site of an Anti-DTPA-Indium Antibody by Equilibrium Binding Immunoassays and Immobilized Metal Ion Affinity Chromatography,”Bioconjugate Chem., 1995, pp. 373-379, vol. 6.
Boerman et al., “Pretargeting of Renal Cell Carcinoma: Improved Tumor Targeting with a Bivalent Chelate,”Cancer Research, Sep. 1, 1999, pp. 4400-4405, vol. 59.
Bosslet et al., “Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy,”Br. J. Cancer, 1991, pp. 681-686, vol. 63.
Carter et al., “Humanization of an anti-p185HER2antibody for human cancer therapy,”Proc. Natl. Acad. Sci. USA, May 1992, pp. 4285-4289, vol. 89.
Casey et al., “Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle,”Br. J. Cancer, 1998, pp. 1307-1312, vol. 78, No. 10.
Chatal et al., “Bifunctional Antibodies for Radioimmunotherapy,”Hybridoma, 1995, pp. 125-128, vol. 14, No. 2.
Colman, “Production of therapeutic proteins in the milk of transgenic livestock,”Biochem. Soc. Symp., 1996, pp. 141-147, No. 63, Great Britain.
Coloma et al., “Design and production of novel tetravalent bispecific antibodies,”Nature Biotechnology, Feb. 1997, pp. 159-163, vol. 15.
De Stasio et al., “Gadolinium in Human Glioblastoma Cells for Gadolinium Neutron Capture Therapy,”Cancer Research, May 15, 2001, pp. 4272-4277, vol. 61.
Denardo et al., “Phage Library-derived Human Anti-TETA and Anti-DOTA ScFv for Pretargeting RIT,”Hybridoma, 1999, pp. 13-21, vol. 18, No. 1.
Doiron et al., “Fluorsecence Bronchoscopy for Detection of Lung Cancer,”Chest, Jul. 1979, pp. 27-32, vol. 76, No. 1.
Feng et al., “New Anti-Cu-TETA and Anti-Y-DOTA Monoclonal Antibodies for Potential Use in the Pre-Targeted Delivery of Radiopharmaceuticals to Tumor,”Hybridoma, 1998, pp. 125-132, vol. 17, No. 2.
Fiedler et al., “High-Level Production and Long-Term Storage of Engineered Antibodies in Transgenic Tobacco Seeds,”Bio/Technology, Oct. 1995, pp. 1090-1093, vol. 13.
Fiedler et al., “Optimization of scFv antibody production in transgenic plants,”Immunotechnology, 1997, pp. 205-216, vol. 3.
Fitzgerald et al., “Improved tumour targeting by disulphide stabilized diabodies expressed inPichia pastoris,” Protein Engineering, 1997, pp. 1221-1225, vol. 10, No. 10.
Gautherot et al., “Therapy for Colon Carcinoma Xenografts with Bispecific Antibody-Targeted, Iodine-131-Labeled Bivalent Hapten,”Cancer, Supplement, Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Oct. 10-12, 1996, pp. 2618-2623.
Goodwin et al., “Pharmacokinetics of Pretargeted Monoclonal Antibody 2D12.5 and88Y-Janus-2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic Acid (DOTA) in BALB/c Mice with KHJJ ouse Adenocarcinoma: A Model for90Y Radioimmunotherapy1,2,”Cancer Research, Nov. 15, 1994, pp. 5937-5946, vol. 54, No. 22.
Goodwin et al., “Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Labeled Bifunctional Haptens,”The Journal of Nuclear Medicine, Feb. 1988, pp. 226-234, vol. 29, No. 2.
Goodwin et al., “Pretargeted Immunoscintigraphy: Effect of Hapten Valency on Murine Tumor Uptake,”The Journal of Nuclear Medicine, Nov. 1992, pp. 2006-2013, vol. 33, No. 11.
Hosono et al., “Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten,”The Journal of Nuclear Medicine, Sep. 1998, pp. 1608-1613, vol. 39, No. 9.
Hosono et al., “Two-Step Targeting and Dosimetry for Small Cell Lung Cancer Xenograft with Anti-NCAM/Antiistamine Bispecific Antibody and Radioiodinated Bivalent Hapten,”The Journal of Nuclear Medicine, Jul. 1999, pp. 1216-1221, vol. 40, No. 7.
Jackson et al., “Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives,”British Journal of Cancer, pp. 181-188, vol. 78, No. 2.
Janevik-Ivanovska et al., “Bivalent Hapten-Bearing Peptides Designed for Iodine-131 Pretargeted Radioimmunotherapy,”Bioconjugate Chem., 1997, pp. 526-533, vol. 8.
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature, May 29, 1986, pp. 522-525, vol. 321.
Karacay et al., “Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA x Murine anti-[In-DTPA] Bispecific Antibody Construct and a99mTc-/188Re-Labeled Peptide,”Bioconjugate Chem., 2000, pp. 842-854, vol. 11.
Kraeber-Bodéré et al., “Bispecific Antibody and Bivalent Hapten Radioimmunotherapy in CEA-Producing Medullary Thyroid Cancer Xenograft,”The Journal of Nuclear Medicine, Jan. 1999, pp. 198-204, vol. 40, No. 1.
Kraeber-Bodéré et al., “Radioimmunotherapy in Medullary Throid Cancer Using Bispecific
Govindan Serengulam V.
Griffiths Gary L.
Hansen Hans J.
Losman Michelle
Qu Zhengxing
Chan Christina
Faegre & Benson LLP
Huynh Phuong
Immunomedics Inc.
LandOfFree
Anti-DOTA antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-DOTA antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-DOTA antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3808952